Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | Erucov-Vac |
Routes of administration | Intramuscular |
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
Turkovac [2] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
In November 2020, Turkovac started on phase I trials with 44 participants in Turkey. [3]
In February 2021, Turkovac started on phase II trials with 250 participants in Turkey. [4]
In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey. [5] As of 2023 [update] phase III trials continue. [6]
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed. [7] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac. [8]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
![]() | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
![]() | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |